Funding

ILiAD Biotechnologies

United States · Biotech

Developing a next-generation pertussis vaccine candidate BPZE1

Visit iliadbio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$115MAI Life Sciences — Role not disclosedBNP Paribas Asset Management Alts — Role not disclosedJanus Henderson Investors — Role not disclosedRA Capital Management — Role not disclosed

Investors

AI Life SciencesSeries BBNP Paribas Asset Management AltsSeries BJanus Henderson InvestorsSeries BRA Capital ManagementSeries B

Coverage

Feb 10, 2026ILiAD Biotechnologies · Series B

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesiliadbio.com ↗